Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study

Purpose Apatinib, a new tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, has shown promising efficacy against several solid cancers, but evidence of its efficacy against relapsed and refractory nasopharyngeal carcinoma is limited. We investigated the efficacy and sa...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Invest New Drugs
Autori principali: Li, Ling, Kong, Fei, Zhang, Lei, Li, Xin, Fu, Xiaorui, Wang, Xinhua, Wu, Jingjing, Zhang, Fangwen, Ren, Liangliang, Zhang, Mingzhi
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer US 2020
Soggetti:
Phase II Studies
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7575486/
https://ncbi.nlm.nih.gov/pubmed/32363427
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-020-00925-2
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi